Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers

[1]  C. Magnant,et al.  Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  F. V. van Leeuwen,et al.  Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. , 2003, Journal of the National Cancer Institute.

[3]  J. Hopper,et al.  Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. , 2003, American journal of human genetics.

[4]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[5]  J. Satagopan,et al.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. , 2002, The New England journal of medicine.

[6]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  K. Heimdal,et al.  Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study , 2000, The Lancet.

[8]  J. Andersen,et al.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.

[9]  J. Klijn,et al.  Survival in hereditary breast cancer associated with germline mutations of BRCA2. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Dobie,et al.  Prophylactic mastectomy for prevention of breast cancer. , 1999, The Journal of family practice.

[11]  L. Norton,et al.  BRCA-associated breast cancer in young women. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[13]  J. Klijn,et al.  Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1 , 1998, The Lancet.

[14]  M. Seller,et al.  Unusual case of Smith-Lemli-Opitz syndrome "type II". , 1995, American journal of medical genetics.

[15]  M. Badzioch,et al.  Bilaterality in familial breast cancer patients , 1985, Cancer.

[16]  B. Fisher,et al.  Pathologic findings from the national surgical adjuvant project for breast cancers (protocol no. 4) X. Discriminants for tenth year treatment failure , 1984, Cancer.

[17]  D. Bishop,et al.  Breast and Ovarian Cancer Incidence in BRCA I -Mutation Carriers , 2007 .

[18]  L. J. Schelven.  Impact of BRCA1 / BRCA2 counseling and testing on newly diagnosed breast cancer patients , 2004 .

[19]  Multi-agent chemotherapy for early breast cancer. , 2002, The Cochrane database of systematic reviews.

[20]  Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium , 1999 .

[21]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[22]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.